219 related articles for article (PubMed ID: 32163676)
21. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Kratochwil C; Bruchertseifer F; Rathke H; Hohenfellner M; Giesel FL; Haberkorn U; Morgenstern A
J Nucl Med; 2018 May; 59(5):795-802. PubMed ID: 29326358
[TBL] [Abstract][Full Text] [Related]
22. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
25. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
[TBL] [Abstract][Full Text] [Related]
26. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
27. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
28. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
29. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
30. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
31. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
32. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
33. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
Schmidkonz C; Atzinger A; Goetz TI; Beck M; Ritt P; Prante O; Kuwert T; Bäuerle T; Cordes M
Clin Nucl Med; 2020 Feb; 45(2):105-112. PubMed ID: 31876822
[TBL] [Abstract][Full Text] [Related]
34. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
35. Response Assessment and Prediction of Progression-Free Survival by
Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768
[TBL] [Abstract][Full Text] [Related]
36. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
38. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
[TBL] [Abstract][Full Text] [Related]
39. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
40. Response assessment using [
Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
